ABSTRACT
COVID-19 presented a crisis for long-term care homes (LTCHs) and retirement homes (RHs). This study explored the pandemic-related challenges LTCHs and RHs faced and the strategies they used to mitigate them. Ninety-one key informant interviews were conducted with LTCH and RH leadership across 47 homes (33 LTCHs, 14 RHs) in Ontario, Canada from February 2021 to July 2022. Findings confirmed evidence for three main challenges. First, leaders were challenged to implement infection prevention and control protocols and measures. Second, they needed supports to facilitate COVID-19 vaccine access and to promote vaccine confidence. Third, LTCH/RH staff experienced significant well-being challenges in the face of COVID-19 pressures. Findings also reveal a plethora of strategies implemented by homes, with ranging reports of perceived success. Homes’ needs evolved rapidly as the COVID-19 pandemic progressed. The use of a co-creation, responsive and tailored approach to address evolving barriers and meaningfully support homes during emergencies is recommended.
Key points
COVID-19 challenges in homes persisted over one year into the pandemic
We describe the IPAC, vaccine and wellness challenges faced by LTCH and RH
We used these data to design a congregate care home support program to navigate COVID-19 challenges
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the COVID-19 Immunity Task Force under Grant #2021-HQ-000143
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Unity Health Toronto gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos